WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it will unveil
Quell™, the Company's wearable pain relief device at the International
Consumer Electronics Show (CES) in Las Vegas in January 2015.
Quell™ Wearable Pain Relief Device (Photo: Business Wire)
Quell™ utilizes NeuroMetrix's proprietary non-invasive neurostimulation
technology to provide relief from chronic pain, particularly neuropathic
pain such as due to diabetes and lower back problems. The advanced
wearable device is lightweight and can be worn during the day while
active, and at night while sleeping. It has been cleared by the FDA for
treatment of chronic pain without a prescription. Users of the device
will also have the option of using their smartphone to automatically
track and personalize their pain therapy. The Company expects Quell™ to
be available for purchase by consumers in the second quarter of 2015.
"We are excited to be on the cusp of entering the $4B US
over-the-counter pain relief market. We believe that as advanced
wearable therapeutic technology, Quell™ represents a new pain relief
category that will be attractive to consumers looking for
non-pharmacological pain control options," said Shai N. Gozani, M.D.,
Ph.D., President and Chief Executive Officer of NeuroMetrix.
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care tests that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. For more information, please visit http://www.NeuroMetrix.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20141119005154/en/
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
